High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial

医学 利福平 肺结核 人口 不利影响 儿科 随机对照试验 意向治疗分析 内科学 外科 环境卫生 病理
作者
Rovina Ruslami,Federica Fregonese,Lika Apriani,Leila Barss,Nancy Bedingfield,Victor Chiang,Victoria Cook,Dina Fisher,Eri Flores,Greg J. Fox,James C. Johnston,Rachel Lim,Richard Long,Catherine Paulsen,Thu Anh Nguyen,Nguyen Viet Nhung,Diana Gibson,Chantal Valiquette,Andrea Benedetti,Dick Menzies
出处
期刊:The Lancet Respiratory Medicine [Elsevier]
卷期号:12 (6): 433-443 被引量:2
标识
DOI:10.1016/s2213-2600(24)00076-6
摘要

Background Tuberculosis preventive treatment (TPT) is a key component of tuberculosis elimination. To improve completion and reduce the burden for people and health systems, short, safe, and effective TPT regimens are needed. We aimed to compare safety and treatment completion of various doses and durations of rifampicin in people who were recommended to receive TPT. Methods This partially blinded, parallel-arm, non-inferiority, randomised, controlled, phase 2b trial was done at seven university-affiliated clinics in Canada, Indonesia, and Viet Nam. Participants aged 10 years or older were included if they had an indication for TPT according to WHO guidelines for Indonesia and Viet Nam, or Canadian guidelines for Canadian sites, and a positive tuberculin skin test or interferon-γ release assay. Participants were randomly assigned (1:1:1) to receive oral rifampicin at 10 mg/kg once daily for 4 months (standard-dose group), 20 mg/kg daily for 2 months (20 mg/kg group), or 30 mg/kg daily for 2 months (30 mg/kg group). The randomisation sequence was computer generated with blocks of variable size (three, six, and nine) and stratified by country for Indonesia and Viet Nam, and by city within Canada. Participants and investigators were masked to dose in high-dose groups, but unmasked to duration in all groups. The two co-primary outcomes were safety (in the safety population, in which participants received at least one dose of the study drug) and treatment completion (in the modified intention-to-treat [mITT] population, excluding those ineligible after randomisation). Protocol-defined adverse events were defined as grade 3 or worse, or rash or allergy of any grade, judged by an independent and masked panel as possibly or probably related to the study. A margin of 4% was used to assess non-inferiority. This study is registered with ClinicalTrials.gov, NCT03988933 (active). Results Between Sept 1, 2019, and Sept 30, 2022, 1692 people were assessed for eligibility, 1376 were randomly assigned, and eight were excluded after randomisation. 1368 participants were included in the mITT population (454 in the standard group, 461 in the 20 mg/kg group, and 453 in the 30 mg/kg group). 589 (43%) participants were male and 779 (57%) were female. 372 (82%) in the standard-dose group, 329 (71%) in the 20 mg/kg group, and 293 (65%) in the 30 mg/kg group completed treatment. No participants in the standard-dose group, one (<1%) of 441 participants in the 20 mg/kg group, and four (1%) of 423 in the 30 mg/kg group developed grade 3 hepatotoxicity. Risk of protocol-defined adverse events was higher in the 30 mg/kg group than in the standard-dose group (adjusted risk difference 4·6% [95% CI 1·8 to 7·4]) or the 20 mg/kg group (5·1% [2·3 to 7·8]). There was no difference in the risk of adverse events between the 20 mg/kg and standard-dose groups (–0·5% [95% CI –2·4 to 1·5]; non-inferiority met). Completion was lower in the 20 mg/kg group (–7·8% [95% CI –13·6 to –2·0]) and the 30 mg/kg group (–15·4% [–21·4 to –9·4]) than in the standard-dose group. Interpretation In this trial, 2 months of 30 mg/kg daily rifampicin had significantly worse safety and completion than 4 months of 10 mg/kg daily and 2 months of 20 mg/kg daily (the latter, a fully blinded comparison); we do not consider 30 mg/kg to be a good option for TPT. Rifampicin at 20 mg/kg daily for 2 months was as safe as standard treatment, but with lower completion. This difference remains unexplained. Funding Canadian Institutes of Health Research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CX完成签到 ,获得积分10
1秒前
kakaC完成签到,获得积分10
2秒前
溟旅发布了新的文献求助10
2秒前
佩奇完成签到,获得积分10
2秒前
orixero应助微笑念寒采纳,获得30
2秒前
3秒前
妙奇完成签到,获得积分10
4秒前
5秒前
共享精神应助产电菌菌主采纳,获得50
5秒前
刻苦绿柏发布了新的文献求助10
5秒前
5秒前
5秒前
2222完成签到,获得积分10
5秒前
天天快乐应助小蚊子采纳,获得10
5秒前
Cybars完成签到 ,获得积分10
5秒前
幽默不愁完成签到,获得积分10
5秒前
冰雪物语完成签到,获得积分10
7秒前
善学以致用应助远了个方采纳,获得10
7秒前
李健应助远了个方采纳,获得10
7秒前
CipherSage应助远了个方采纳,获得10
7秒前
细心的小懒虫完成签到,获得积分10
7秒前
神勇映安完成签到,获得积分10
7秒前
求知小生完成签到,获得积分10
7秒前
8秒前
畅快访蕊发布了新的文献求助10
8秒前
9秒前
song完成签到,获得积分10
9秒前
10秒前
英姑应助yylum采纳,获得10
10秒前
awang完成签到,获得积分10
11秒前
如约而至完成签到 ,获得积分10
11秒前
heguangjie完成签到,获得积分10
11秒前
dghcmh完成签到,获得积分10
12秒前
12秒前
八花完成签到,获得积分10
12秒前
camellia完成签到 ,获得积分10
13秒前
13秒前
CarolineOY完成签到,获得积分10
14秒前
顺利完成签到,获得积分10
14秒前
愉快的冰萍完成签到 ,获得积分10
15秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3099877
求助须知:如何正确求助?哪些是违规求助? 2751333
关于积分的说明 7612942
捐赠科研通 2403282
什么是DOI,文献DOI怎么找? 1275217
科研通“疑难数据库(出版商)”最低求助积分说明 616310
版权声明 599053